Among the topics that have been mooted for the reforms is the possible introduction of patent term extensions where the commercial exploitation of a pharmaceutical or agrochemical product is delayed due to the need to obtain regulatory approval. It has been noted that the Select Committee makes no recommendation in this regard. This omission is particularly disappointing for patentees because the Bill contains two 'spring-boarding' provisions. These are clause 136, which will grant an exemption from infringement for an act done for experimental purposes, and clause 138, which will govern the development and submission of information required to obtain regulatory approval.
The Committee's report will be debated in Parliament before a decision is made to amend the Patents Bill.
Source: Adrian Evans (Henry Hughes Patent & Trade Mark Attorneys).
The Committee's report will be debated in Parliament before a decision is made to amend the Patents Bill.
Source: Adrian Evans (Henry Hughes Patent & Trade Mark Attorneys).
No comments:
Post a Comment